Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
Data ReadoutpositiveTRUTAKNAPositive
AI Analysis
Summary
Vera Therapeutics announced positive Phase 3 final efficacy data from the ORIGIN 3 trial showing TRUTAKNA (atacicept-vymj) stabilized eGFR and prevented IgA nephropathy disease progression through two years of treatment.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
TRUTAKNA stabilized eGFR and prevented kidney disease progression through two years in ORIGIN 3 final efficacy analysis
Importance:8/10
Sentiment:
0.85
Phase 3IgA Nephropathykidney diseaseefficacy dataORIGIN 3 trial
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on September 15, 2026 10:30 AM